FDA Approves Dysport for Upper Limb Spasticity in Children

The U.S. Food and Drug Administration (FDA) has expanded the use Dysport (botulinum toxin type A) to include the treatment of upper limb spasticity in children two years of age and older, excluding spasticity caused by cerebral palsy. The FDA previously approved...

Autism Versus Phelan-McDermid Syndrome

Dianne Linnehan, Director of Operations of the Phelan McDermid Syndrome Foundation discusses this rare genetic condition due to mutations in chromosome 22. In most cases, the mutations are de novo and the variety of mutations leads to a large array of symptoms and their severity.

Jansen’s Disease Research Update

Neena Nizar, PhD, discusses Jansen’s metaphyseal chondrodysplasia, an extremely very rare autosomal dominant disease. It is a type of skeletal dysplasia characterized by short-limbed short stature, waddling gait, bowed legs, contracture deformities of the joints, short hands, clubbed fingers, clinodactyly, prominent upper face and small mandible features.

Fibromuscular Dysplasia (FMD) Overview

Jeffrey W Olin, DO is a Professor of Medicine at the Icahn School of Medicine at Mount Sinai, provides an overview of fibromuscular dysplasia (FMD), a rare condition characterized by abnormal development or growth of cells in the walls of blood vessels (arteries) that can cause the vessels to narrow.

Approved and Emerging Therapies for Mucopolysaccharidoses (MPS)

Heather A. Lau, MD, Director, Lysosomal Storage Disease Program at NYU Langone Health, discusses some of the approved and emerging therapies for mucopolysaccharidoses (MPSs), a group of rare, inherited lysosomal storage disorders that are clinically characterized by abnormalities in multiple organ systems and reduced life expectancy.

  • Sign up
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
We do not share your personal details with anyone.